Elham Moases Ghaffary

Elham Moases Ghaffary

Auto-generated profile, based on publicly available information

Elham Moases Ghaffary

Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2023 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
SBSara Bagherieh
Sara Bagherieh
AAAlireza Afshari-Safavi
Alireza Afshari-Safavi
SVSaeed Vaheb
Saeed Vaheb
MKMahsa Kiani
Mahsa Kiani
EGElham Moases Ghaffary
Elham Moases Ghaffary
OMOmid Mirmosayyeb
Omid Mirmosayyeb

31 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NNNiraj Neupane
Niraj Neupane
SBSawyer Bawek
Sawyer Bawek
SGSayuri Gurusinghe
Sayuri Gurusinghe
EGElham Moases Ghaffary
Elham Moases Ghaffary
OMOmid Mirmosayyeb
Omid Mirmosayyeb
ADAjay Dhakal
Ajay Dhakal
Breast cancer is the most common cancer among women worldwide, and estrogen receptor-positive (ER+) breast cancer accounts for a significant proportion of cases. While various treatments are available, endocrine therapies are often the first-line treatment for this type of breast cancer. However, the development of drug resistance poses a significant challenge in managing this disease. ESR1 mutations have been identified as a common mechanism of endocrine therapy resistance in ER+ breast cancer. The first-generation selective estrogen receptor degrader (SERD) fulvestrant has shown some activity against ESR1 mutant tumors. However, due to its poor bioavailability and need for intramuscular injection, it may not be the optimal therapy for patients. Second-generation SERDs were developed to overcome these limitations. These newer drugs have improved oral bioavailability and pharmacokinetics, making them more convenient and effective for patients. Several oral SERDs are now in phase III trials for early and advanced ER+ breast cancer. This review summarizes the background of oral SERD development, the current status, and future perspectives.


17 September 2022 in Canadian Journal of Infectious Diseases and Medical Microbiology
Verified
Journal Article
Open access
OMOmid Mirmosayyeb
Omid Mirmosayyeb
EGElham Moases Ghaffary
Elham Moases Ghaffary
MMMahsa Mazdak
Mahsa Mazdak
ZBZahra Bagheri
Zahra Bagheri
SBSara Bagherieh
Sara Bagherieh
VSVahid Shaygannejad
Vahid Shaygannejad
Is Myasthenia Gravis a Real Complication of the COVID-19 Vaccine? A Case Report-Based Systematic Review: Background. Myasthenia gravis (MG) is a neuromuscular, autoimmune disease that causes weakness by impairing neuromuscular transmission. According to reports, vaccines can lead to autoimmunity in different ways, and COVID-19 vaccines are suggested to trigger MG. We conducted this systematic review to assess MG patients after the COVID-19 vaccination. Methods. We collected 231 studies from four databases from inception to 26 March 2022. Results. 4 case studies were selected from 231 research studies, and data were extracted based on inclusion criteria. In all cases, MG was reported following COVID-19 vaccination. Symptoms such as muscle weakness, numbness, and ptosis were common. The MG was confirmed through RNST, MRC, NCS, and AchR-binding antibody titer tests. Conclusion. Although all cases of MG were diagnosed following appropriate tests, the sample size was small; therefore, further investigation is required to demonstrate the possible association between MG and COVID-19 vaccination.

1 January 2024 in Acta Neurologica Scandinavica
Verified
Journal Article
Open access
YMYousef Mokary
Yousef Mokary
SVSaeed Vaheb
Saeed Vaheb
MPMohammad Yazdan Panah
Mohammad Yazdan Panah
AAAlireza Afshari-Safavi
Alireza Afshari-Safavi
EGElham Moases Ghaffary
Elham Moases Ghaffary
OMOmid Mirmosayyeb
Omid Mirmosayyeb
Background: Dysfunctions of the hypothalamic‐pituitary‐adrenal (HPA) axis can trigger multiple sclerosis (MS) symptoms. Mood disorders comorbid with MS are implicated in the HPA axis activation in most people with MS (pwMS). This study purposed to examine salivary cortisol (SC) levels and their association with mood disorders in pwMS. Methods: Forty‐three men as pwMS and sixteen men as healthy controls (HC) were included in this study. pwMS and HC completed the Beck Depression Inventory (BDI), 36‐Item Short Form Survey (SF‐36), Fatigue Severity Scale (FSS), Depression Anxiety and Stress Scale, and Hospital Anxiety and Depression Scale questionnaires. SC levels were also measured in pwMS and HC. A linear regression model was used to analyze the relationship between the Expanded Disability Status Scale (EDSS) and mood disorders and SC levels. Pearson’s or Spearman’s tests examined the correlation between SC levels and mood disorders. Results: The SC level, anxiety, depression, fatigue, and stress were significantly higher in pwMS than in HC ( p < 0.05). pwMS also showed significant correlations between SC levels and role physical ( r = 0.3, p < 0.05) and emotional ( r = 0.34, p < 0.05) in SF‐36. Among SF‐36 domains, only general health ( β = −0.72, p < 0.05) and physical functioning ( β = −1.61, p < 0.05) were negatively associated with disease duration. No correlation was found between SC levels and anxiety, depression, and fatigue ( p > 0.05). Conclusions: The pwMS showed mild to moderate depression, anxiety, and fatigue. Only general health and physical functioning as aspects of quality of life were related to disease duration, while SC levels, mood disorders, and other quality‐of‐life domains were not associated with clinical characteristics. Also, this study failed to find a significant role for SC as a valuable marker in approaching mood disorders in pwMS.

18 December 2023 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
YMYousef Mokary
Yousef Mokary
SVSaeed Vaheb
Saeed Vaheb
MPMohammad Yazdan Panah
Mohammad Yazdan Panah
AAAlireza Afshari-Safavi
Alireza Afshari-Safavi
EGElham Moases Ghaffary
Elham Moases Ghaffary
OMOmid Mirmosayyeb
Omid Mirmosayyeb